The Bench Under Suspicion: A Structured Response to Suspected Pseudo-Outbreaks
A rising number of positive results is, rightly, treated as a signal. In most circumstances it points to something happening in patients. Occasionally, however, the pattern originates closer to home: on the bench, in a reagent bottle, within an automated platform or along a specimen pathway that has quietly changed. The laboratory then faces a difficult double duty. It must avoid dismissing a genuine cluster, and it must avoid amplifying a laboratory artefact into a ward-level emergency. A pseudo-outbreak is not a lesser event. It is a different event, and it requires a deliberate response.
Define the question before the investigation defines you
The trigger may be a run of indistinguishable isolates, an unexpected rise in a particular specimen type, or a clinician asking why several patients on one ward have suddenly converted. The first step is not to decide whether the cluster is real. It is to define what is being counted. Agree a working case definition, compare the current rate with the established baseline, and stratify by specimen type, collection device, ward, processing batch, media lot, stain batch, analytical platform, shift and reporting consultant. A pattern that follows a patient group suggests clinical transmission. A pattern that follows a batch, a bench or a technician suggests a laboratory source. Many investigations reveal a mixture of both.
Run patient safety and laboratory verification in parallel
Delay is the most common error. If there is any plausible clinical risk, infection prevention and control teams should be informed early, with the uncertainty stated plainly. The message should not be “there may be a false alarm”; it should be “the laboratory is investigating a possible change in result pattern, and IPC action should proceed on clinical grounds while verification continues.” In practice, this means two tracks. The clinical track supports ward-level review, repeat sampling where appropriate, and clear advice on interpreting results that may later be revised. The laboratory track examines contamination, carryover and process failure. Neither track should wait for the other to finish before taking proportionate action.
Sample the environment with a hypothesis, not a scattergun
Environmental sampling is often performed too broadly and interpreted too loosely. Before swabs are taken, identify the most likely points of entry: staining benches, incubator surfaces, water baths, refrigerated centrifuges, automated staining and processing instruments, shared pipettes, waste routes and hand-contact surfaces. Sample those sites alongside negative controls, and record the exact location, time, operator and method. Reagent and stain checks matter equally. Review lot numbers, expiry dates, preparation records, storage conditions and in-use dating. Examine whether Gram stains, auramine-phenol stains or mycobacterial preparations are showing unexpected background fluorescence or precipitate. For molecular workflows, scrutinise extraction controls, negative controls, plate layout and carryover risks between high-load and low-load samples. A positive environmental result is not proof of causation; it is a line of evidence that must fit the epidemiological and workflow picture.
Walk the whole pathway, not just the bench
Pseudo-outbreaks frequently arise from changes that no single person owns. A new collection device, a different transport medium, a revised accessioning rule, a replacement incubator, a maintenance visit or a change in how plates are read can all alter the apparent rate of positives. Observe the pathway from collection to reporting, not only the moment of culture. Ask what changed in the preceding weeks, including staffing, training, consumables, equipment, water supply and ventilation. Review audit trails and batch records for temporal clustering. Interview staff without a blame frame; human factors often explain why a deviation was invisible until results changed. The aim is not to find a culprit but to find a mechanism.
Make communication a clinical control
Clear communication is not public relations; it is part of safe patient care. Appoint a single laboratory point of contact, issue short daily updates even when there is little new information, and state what is known, what is not known and what clinicians should do next. Where results may be affected, advise on repeat sampling and interpretation rather than withdrawing all results reflexively. If the pattern has public health implications, engage the relevant UK health protection arrangements early. Document decisions and their rationale, including why a result was or was not reported, because the audit trail will matter if the conclusion is later challenged.
Close with a verified conclusion and residual risk
Investigations should end with an explicit outcome: true outbreak, pseudo-outbreak, mixed picture, or unresolved with ongoing monitoring. A pseudo-outbreak conclusion still deserves corrective action, change control and shared learning. Revalidate affected processes, update standard operating procedures, reinforce training and set a review period to confirm that the rate has returned to baseline. The laboratory protects patients twice over in these episodes: first by refusing to let a laboratory signal masquerade as clinical truth, and second by refusing to let the possibility of contamination become an excuse for inaction. The bench can be the source, but it can also be the safeguard.
